The role of functional assessment as an outcome measure in antidementia treatment.
Functional assessment refers to the evaluation of performance in basic activities of daily living, instrumental activities of daily living, professional duties, and hobbies. This assessment is particularly relevant in the evaluation of cognitive impairment. In fact, functional decline represents a core feature of dementia according to the DSM-IV criteria. Clinically, functional deterioration represents a diagnostic marker, can be used to chart the course of the disease, and as a prognostic marker as it contributes significantly to caregiver burden and institutionalization. For all these reasons, functional assessment has been widely used as an outcome measure in intervention trials of Alzheimer disease (AD). Appropriate function assessment scales have been developed for use in clinical trials of AD. Studies have shown that functional decline benefits from pharmacological interventions in AD and some other cognitive syndromes. This benefit translates into a stabilization ranging between 6 to 12 months compared to a gradual deterioration in the placebo group. There is rarely reversibility for IADL's lost. There are no functional scales specifically designed for assessment of subjects with non-AD cognitive impairment. Scales specifically developed for Mild Cognitive Impairment and other dementias are needed.
Massoud
Fadi
F
Service de Gériatrie, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada.
D002170:Canada; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards; D003072:Cognition Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D003704:Dementia / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D009483:Neuropsychological Tests / Q000592:standards*; D018697:Nootropic Agents / Q000627:therapeutic use*; D010043:Outcome and Process Assessment, Health Care / Q000379:methods* / Q000592:standards; D015990:Placebo Effect; D011237:Predictive Value of Tests
D018697:Nootropic Agents